Advancing Regenerative Medicine
SMSbiotech is a clinical-stage regenerative medicine company developing a first-in-class Small Mobile Stem (SMS) cell therapy platform. Its lead COPD program has demonstrated early safety and encouraging efficacy signals in Phase 1b and is advancing toward U.S. clinical development and Phase 2. SMSbiotech’s platform expansion includes the development of therapies for osteoarthritis, lung fibrosis, and other degenerative diseases.
Small Mobile Stem (SMS) cells, derived from adult human blood, are designed as an allogeneic, off-the-shelf therapy with the ability to engage key regenerative pathways that are relevant to widespread chronic diseases affecting health and longevity. The platform is built to overcome limitations of existing regenerative cell therapies while enabling scalable, repeatable treatment approaches.
Democratizing the application of adult stem cell technologies for human health.
Regenerative Medicine Enabled by a Novel superior Stem Cell Technology
join usCurrently, many conventional drugs and treatments address patients’ symptoms instead of the root causes of the disease. This approach can result in ongoing health issues like non-healing wounds, degenerative tissues or diseases we merely live with like Chronic Obstructive Pulmonary Disease (COPD), a third leading cause of death worldwide. About 3.5 million death every year according to the WHO. In addition, this treatment approach contributes to significant healthcare costs in the U.S., totaling approximately $24 billion in medical expenses, as reported by the American Lung Association. (can label source at bottom of page: Shah et al. Direct Medical Costs of COPD in the USA: An Analysis of the Medical Expenditure Panel Survey 2017-2018; AHEHP 2023)
SMSbiotech’s patented regenerative technology intends to change this status quo. Its transformative approach addresses the lack of ability of many patients to restore cells and tissues damaged by disease, trauma, and normal aging to positively affect their quality-of-life health span and longevity.
A novel, patented approach that produces unique human allogeneic adult Small Mobile Stem (SMS) cells.
The backbone of our treatments
Stem cell enabling technology. Delivering life-changing treatments from human stem cells with unique properties and derived complex proteins.
more infoA novel, patented approach that produces unique human allogeneic adult Small Mobile Stem (SMS) cells.
The challenges
Tissue degeneration is at the root of many chronic, age-related diseases such as COPD, ARDS, chronic wounds, reduced health span and longevity.
more info
Our technological
solutions
Cutting edge technology addressing the two essential components of living tissue; cells and extracellular matrix using a unique mode of action.
more infoManufactures cells for therapeutic use at an industrial scale. These cells can potentially address many widespread chronic lung diseases such as COPD.
Who we are
SMSbiotech is a clinical-stage regenerative medicine company founded in 2015 and based in Carlsbad, California. The Company is advancing a proprietary Small Mobile Stem (SMS) cell therapy platform designed to enable systemic, off-the-shelf regenerative treatments for multiple indications.
The platform is based on SMSbiotech’s discovery of a novel population of adult stem cells originally derived from human adult blood and protected by a growing global patent portfolio. SMS cells are able to target cells that are key to tissue regeneration and are designed to support scalable manufacturing, stability, and repeatable dosing, addressing key limitations of traditional regenerative cell therapies.
SMSbiotech has established clinical-stage biomanufacturing capabilities, including ISO-7 clean room infrastructure, enabling controlled, reproducible production aligned with regulatory requirements. SMS cells are native, non genetically manipulated, cells capable of extensive ex vivo expansion without loss of potency, supporting the potential for industrial-scale manufacturing.
The Company is currently advancing its lead COPD program through Phase 1b clinical development, with early safety and encouraging efficacy signals observed. SMSbiotech is focused on progressing toward U.S. regulatory pathways and expanding into Phase 2 clinical studies.
Our world-class leadership team brings together deep expertise in regenerative biology, clinical development, global business, and capital markets, united by a commitment to translating scientific discoveries into clinically meaningful therapies for chronic, debilitating, and degenerative diseases that affect hundreds of millions of patients worldwide.
Do you want to learn more about us? Contact us!
